Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Dr. Natalia Marina CARDILLO, USDA-ARS-WSU, United States

Dr. Natalia Marina Cardillo is a distinguished veterinary scientist from Argentina with a Ph.D. in Veterinary Sciences, specializing in parasitology and public health 🧫. Currently a Postdoctoral Research Associate at Washington State University 🇺🇸, she focuses on chemotherapeutic strategies for bovine babesiosis. With over two decades of academic and research excellence across UBA, CONICET, INTA, and USDA, she has led groundbreaking projects on zoonoses, antiparasitic drug resistance, and diagnostics. 🧬 Her contributions span teaching, diagnostics, and pharmaceutical clinical trials in veterinary medicine, earning her global recognition and prestigious fellowships.

Publication Profile

Google Scholar

Education

Dr. Natalia Marina Cardillo began her academic path with a Doctor of Veterinary Medicine degree (1997–2004) from the Universidad de Buenos Aires, Argentina, specializing in Public Health 🐕‍🦺🩺. She furthered her expertise by completing a Ph.D. in Veterinary Sciences with a focus on Parasitology and Public Health (2006–2012), earning the prestigious “summa cum laude” distinction for her thesis on Toxocara cati in murine models 🧬🧫. To complement her academic and research proficiency, she pursued a University Teaching Major in Veterinary and Biological Sciences (2014–2016), strengthening her role as an educator and mentor 📚👩‍🏫.

Experience

Dr. Natalia Marina Cardillo has led a distinguished career in parasitology, veterinary microbiology, and public health. Currently a Postdoctoral Research Associate at Washington State University 🐄💊, she focuses on developing novel treatments for bovine babesiosis. Previously, she served as Senior and Principal Scientist at CONICET-INTA 🇦🇷, leading studies on zoonotic parasitic diseases. With over two decades of academic roles at the Universidad de Buenos Aires 👩‍🏫🧫, she also contributed significantly to diagnostics, laboratory accreditation, and veterinary clinical trials. As founder of ALIANZA InVet 🧬🐕, she has pioneered ethical animal research and advanced pharmaceutical testing across Argentina.

Awards

Dr. Natalia Marina Cardillo has received numerous prestigious honors throughout her career. From 2023 to 2025, she was awarded a competitive Postdoctoral Fellowship by the USDA at Washington State University 🇺🇸🔬. In 2018, she won the NAVES entrepreneurship competition by Universidad Austral’s IAE Business School for her CRO-VET project 🏅💼. Her academic excellence was recognized early with a Ph.D. fellowship (2005–2010) in Public Health Veterinary Medicine and a Scientific Research Scholarship (2000–2002) in Parasitology at Universidad de Buenos Aires 🇦🇷📘—highlighting her dedication to veterinary science and innovation.

Research Focus

Dr. Natalia Marina Cardillo’s research is rooted in veterinary parasitology, with a strong emphasis on zoonotic diseases, public health, and epidemiology 🐛🧫🌍. Her work investigates parasites like Toxocara cati, Trichinella spp., and Aelurostrongylus abstrusus, exploring their life cycles, transmission, and pathology in animal hosts and their public health implications 💉📊. She also focuses on developing chemotherapeutic treatments for diseases such as bovine babesiosis, integrating pharmacology, immunology, and molecular diagnostics 🧬💊. Her interdisciplinary research contributes significantly to One Health, bridging human, animal, and environmental health.

Publication Top Notes

Prevalence of Toxocara cati and other parasites in cats’ faeces collected from the open spaces of public institutions: Buenos Aires, Argentina

Trichinella infection in wild animals from endemic regions of Argentina

Experimental Infection with Toxocara cati in BALB/c Mice, Migratory Behaviour and Pathological Changes

Prevalence of canine dirofilariosis in the city of Buenos Aires and its outskirts (Argentina)

Evaluation of the risk of transmission of Trichinella in pork production systems in Argentina

First report of Toxocara cati in the domestic land snail Rumina decollata

Soil contamination with eggs of Toxocara species in public parks of Karaj, Iran

Clinical, haematological, biochemical and economic impacts of Trichinella spiralis infection in pigs

First report of Aelurostrongylus abstrusus in domestic land snail Rumina decollata, in the Autonomous city of Buenos Aires

EXPERIMENTAL INFECTION WITH Toxocara cati IN PIGS: MIGRATORY PATTERN AND PATHOLOGICAL RESPONSE IN EARLY PHASE

Nuevos aportes al conocimiento de Trichinella y trichinellosis

Nitika Mor | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Nitika Mor | Drug Discovery and Development | Best Researcher Award

Dr. Nitika Mor, Baba Mastnath University, Asthal Bohar, Rohtak (HR), India

Dr. Nitika Mor is an accomplished Assistant Professor of Chemistry at Baba Mastnath University, Rohtak, with a Ph.D. in Pharmaceutical Chemistry from Kurukshetra University. Her research focuses on drug delivery systems, traditional medicinal formulations, and molecular docking. She has published 14 research papers, authored a book chapter, holds two patent publications (one granted), and has received multiple awards including the UGC-CSIR JRF/SRF and Best Poster Award. With technical expertise in synthesis, biological assays, and in-silico studies, Dr. Mor is a dynamic contributor to pharmaceutical research and innovation.

Publication Profile

Google Scholar

Education

Dr. Nitika Mor is a dedicated researcher with a Ph.D. in Chemistry from Kurukshetra University (2017–2022), where she focused her thesis on the Design, Characterization, and In-Vitro Studies of Sustained Release Delivery Systems for Curcumin under the guidance of Dr. Neera Raghav. 🎓 She holds an M.Sc. in Organic Chemistry (2013–2015) from Hindu College, Sonipat, affiliated with Maharishi Dayanand University, Rohtak. 🧪 Her academic journey began with a B.Sc. in Physics, Chemistry, and Mathematics (2010–2013) from Hindu Girls College, Sonipat. 📚 Dr. Mor’s educational background reflects a strong foundation in science and innovative pharmaceutical research.

Experience

Dr. Nitika Mor is currently serving as an Assistant Professor in the Department of Chemistry at Baba Mastnath University, Rohtak, since February 1, 2023. 🏛️ With her strong academic foundation and research expertise in pharmaceutical and organic chemistry, she brings innovative teaching methods and deep subject knowledge to the classroom. 🧪 Her role involves mentoring students, delivering engaging lectures, and contributing to the academic growth of the department. 📚 Dr. Mor’s commitment to education and passion for chemistry make her a valuable asset to the university’s faculty. ✨ She continues to inspire budding scientists through her teaching and guidance.

Awards

Dr. Nitika Mor has received several prestigious awards and fellowships in recognition of her academic excellence and research potential. She qualified the UGC-CSIR JRF (Chemical Sciences) in June 2016 with an impressive All India Rank of 65. 🇮🇳 She was awarded the Junior Research Fellowship (JRF) from October 2017 to September 2019, followed by the Senior Research Fellowship (SRF) from October 2019 to March 2022 by UGC-CSIR India to support her Ph.D. journey. 🔬 In 2018, she received the Best Poster Presentation Award at the 9th National Conference on RACES-2018 held at MMM College, Patiala, Punjab.

Research Focus

Dr. Nitika Mor specializes in pharmaceutical and biomedical sciences, with a strong research focus on natural polymer-based oral drug delivery systems. Her work emphasizes the use of biopolymers like cellulose, pectin, carrageenan, and alginate for sustained release formulations, particularly for curcumin. She explores modifications of polysaccharides and curcumin derivatives to improve bioavailability, pharmacokinetics, and therapeutic efficacy. Her contributions also span phytochemistry, investigating medicinal plants like Ashwagandha and Garlic for their pharmacological benefits. Dr. Mor integrates green chemistry, molecular modeling, and clinical insights into her innovative drug delivery strategies.

Publication Top Notes

Recent advances in cellulose, pectin, carrageenan and alginate-based oral drug delivery systems

Some cetyltrimethylammonium bromide modified polysaccharide supports as sustained release systems for curcumin

Design and development of carboxymethylcellulose ester of curcumin as sustained release delivery system in liver

Synthesis of propynyloxy substituted some novel aurones as potent cathepsin B inhibitors

Alginate hydrogels: Sustained release system to analyze the effect of traditional excipients on curcumin availability

Study on enhanced serum protein protecting and anti-cathepsin activities of various curcumin formulations containing traditional excipients and bio-enhancers

In-vitro simulation of modified-alginate ester as sustained release delivery system for curcumin

Curcumin, the panacea: A review on advancement to solve pharmaco-kinetic problems.

A review: Phytochemicals and bioactivities of Ashwagandha (Withania somnifera).

Minjian Chen | Pharmacodynamics | Best Researcher Award

Published on by Top Pharmaceutical

Minjian Chen | Pharmacodynamics | Best Researcher Award

Prof. Dr. Minjian Chen, Nanjing Medical University, China

Prof. Dr. Minjian Chen is a distinguished toxicologist and professor at Nanjing Medical University. He earned his Ph.D. in Toxicology (2013) and has led pioneering research on male infertility and birth defects using metabolomics and exposomics. He has completed over 10 major research projects, including NSFC and China’s National Key R&D programs, and holds 4 national patents. Recognized in Jiangsu’s “Qinglan Project,” he has international experience, including research at the U.S. NIEHS. With an H-index of 36, Prof. Chen is a rising leader in environmental health science and precision diagnostics.

Publication Profile

Scopus

Education

Prof. Dr. Minjian Chen 🎓 earned his Bachelor’s degree in Preventive Medicine (2003–2008) and Ph.D. in Toxicology (2008–2013) from Nanjing Medical University (NMU). He completed postdoctoral training (2013–2018) at NMU’s School of Basic Medicine and was selected for the China–Australia Young Scientist Exchange Program in 2014 🌏. From 2019 to 2020, he served as a guest researcher at the U.S. National Institute of Environmental Health Sciences (NIEHS), NIH 🧪. Appointed as a Lecturer in 2013 and promoted to Professor in 2023 at NMU, he is honored as an Outstanding Young Backbone Teacher under Jiangsu’s “Qinglan Project” and a Distinguished Young Academic Leader 🌟.

Professional Memberships

Prof. Dr. Minjian Chen 🧑‍🔬 holds several prominent positions in the scientific community. He serves as the Vice Secretary-General of the Evidence-based Toxicology Professional Committee with the Chinese Society of Toxicology ⚖️. As an Executive Member of the Third Youth Committee of the same society, he actively contributes to advancing toxicology research. He is also a member of the Fertility Preservation and Restoration Professional Committee with the China Association of Obstetrics and Gynecology 👶. Additionally, he is part of multiple professional committees, including the Mutagenesis Professional Committee and the Jiangsu Provincial Preventive Medicine Association 🌱. He is the Vice Chair of the Youth Committee for the Jiangsu Provincial Society of Toxicology.

Research Focus

Prof. Dr. Minjian Chen’s research primarily focuses on metabolomics and environmental toxicology, investigating how chemical exposures disrupt metabolic processes, especially during critical developmental stages. His work includes examining the effects of substances like PFOS (perfluorooctane sulfonate) on embryonic development, exploring metabolic changes in oocyte growth, and understanding spermatogenesis in mice. Dr. Chen also studies pharmacology by analyzing the urate-lowering effects of compounds like delphinidin-3-glucoside. His integrated approach to omics technologies provides insights into how environmental chemicals alter metabolism, offering potential clinical implications. His contributions are crucial for advancing ecotoxicology, metabolic disorders, and biochemical research.

Publication Top Notes

Metabolic characterizations of PFOS-induced disruptions in early embryonic development

Association of Personal Care and Consumer Product Chemicals with Long-Term Amenorrhea: Insights into Serum Globulin and STAT3

Characterization of Metabolic Patterns in Mouse Spermatogenesis and Its Clinical Implications in Humans

Multi-Omics Reveal the Metabolic Changes in Cumulus Cells During Aging

Urate-lowering effect of delphinidin-3-glucoside in red kidney beans via binding to the FAD site of the XO enzyme

Integrative Omics Reveals the Metabolic Patterns During Oocyte Growth

The global phosphorylation landscape of mouse oocytes during meiotic maturation

Environmental Chemical Exposomics and Metabolomics in Toxicology: The Latest Updates

Characterization of metabolic patterns in porcine cumulus cells during meiotic maturation

Exposure to Molybdate Results in Metabolic Disorder: An Integrated Study of the Urine Elementome and Serum Metabolome in Mice

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

Yu Liu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry 🧪 at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences 🎓. He was enrolled as a full-time student from September 2008 to July 2011 📅. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree 🎖️. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development 💊. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences 🔬.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director 🏛️ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center 🔬. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research 💊. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry 🧪. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry 🌍.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees 🏛️, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics 📊. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare 💡💰. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements 💊. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems 🌍.

Research Focus

Yu Liu’s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine

Shanthi Veerappapillai | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Shanthi Veerappapillai | Drug Discovery and Development | Best Researcher Award

Dr Shanthi Veerappapillai, Vellore Institute of Technology, India

Dr. Shanthi Veerappapillai is a distinguished Professor at VIT University, specializing in Bioinformatics and Computational Biology. With a Ph.D. from VIT, her research interests include computational protein analysis, drug resistance studies, and virtual screening, particularly focusing on infectious diseases like HIV and tuberculosis. She has led multiple funded research projects and published over 130 peer-reviewed articles. Dr. Veerappapillai has been recognized with awards like the Women Achiever Award for Sponsored Research Excellence (2020) and has supervised numerous Ph.D. graduates. Her dedication to education and research is also reflected in her active participation in conferences and professional societies. 👩‍🔬📚💻🌍

Publication Profile

Google Scholar

Education Qualification

Dr. Shanthi Veerappapillai holds a Ph.D. in Bioinformatics from VIT University, Tamil Nadu, India, and an M.Tech in Chemical Process and Design from SASTRA University, Tamil Nadu, India. She also earned a B.Tech in Chemical Engineering from EGS Pillai Engineering College, Bharathidasan University, Tamil Nadu, India. With a strong foundation in both chemical engineering and bioinformatics, Dr. Veerappapillai brings a multidisciplinary approach to her research and academic work. Her diverse academic background equips her with the expertise to bridge the gap between technology and biology, contributing to advancements in various scientific fields. 🧬⚙️🎓

Leadership in Research

Dr. Shanthi Veerappapillai is a dedicated scientist with extensive leadership experience as Principal Investigator (PI) in multiple prominent projects. Her research spans critical areas such as drug repurposing strategies and cancer research, showcasing her expertise in advancing both medical and computational biology. Through her work, she has contributed significantly to the development of innovative therapeutic approaches, emphasizing her commitment to enhancing healthcare and medical research. Her ability to lead and collaborate on large-scale projects underscores her impact in the field, making her a valuable asset in shaping the future of medical science and computational biology. 🧬🔬💊

Mentorship and Teaching

Dr. Shanthi Veerappapillai is a distinguished academic with vast experience in supervising successful Ph.D. candidates and teaching specialized subjects in biotechnology and bioinformatics. Her dedication to fostering academic development is evident in her role as a mentor to future researchers. With a passion for guiding students through advanced research topics, she has contributed significantly to shaping the next generation of experts in her field. Her work in biotechnology and bioinformatics continues to inspire students, encouraging innovation and critical thinking in these dynamic disciplines. 👩‍🔬📚🎓🔬👩‍💻

Community Engagement

Dr. Shanthi Veerappapillai is a dedicated academician who has made significant contributions to the scientific community through her active involvement in organizing conferences and workshops. As a member of various professional bodies, Dr. Veerappapillai continuously strengthens her presence in the academic world, sharing her expertise and collaborating with fellow researchers. Her commitment to advancing knowledge and fostering professional connections has had a lasting impact on her field. With a focus on promoting growth in the academic and scientific community, Dr. Veerappapillai’s efforts continue to inspire others. 🌍🧑‍🏫📚

Awards and Achievement

Dr. Shanthi Veerappapillai is a distinguished researcher with 131 peer-reviewed journal articles and an H-index of 14. She received the Best Chapter Award from BRSI-VIT for her exceptional contributions in 2023. She was honored with the Women Achiever Award for Sponsored Research Excellence in 2020 and has been a Research Fellow at INTI International University, Malaysia since June 2023. Dr. Veerappapillai’s academic journey includes producing 100% results in Chemical Engineering Thermodynamics courses and securing university ranks and prizes for academic excellence. She has also received several accolades, including a Best Poster Presentation Award at VIT University. 🏆📚👩‍🔬🌟

Research Focus

Dr. V. Shanthi’s research primarily focuses on molecular simulation, bioinformatics, and computational approaches to drug discovery. She has explored mechanisms of drug resistance, particularly in influenza virus neuraminidase, using molecular simulations to understand oseltamivir resistance. Her work also spans polypharmacology, investigating therapeutic agents for non-small cell lung cancer, and the identification of potential inhibitors for various viruses like H5N1. Additionally, she has contributed to bioprocess industry applications, drug repurposing, and plant-based therapeutic compounds. Her research aims at enhancing drug design, discovering novel therapeutic agents, and understanding the molecular interactions that govern drug efficacy. 🔬💊🦠💡

Publication Top Notes

Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach

Current progress and future perspectives of polypharmacology: From the view of non-small cell lung cancer

Bioactive Amento flavone isolated from Cassia fistula L. leaves exhibits therapeutic efficacy

Application of heat exchangers in bioprocess industry: a review

Multi-dimensional screening strategy for drug repurposing with statistical framework—a new road to influenza drug discovery

Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach

Role of the cation-π interaction in therapeutic proteins: A comparative study with conventional stabilizing forces

 

 

 

Victor Ajayi | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Victor Ajayi | Drug Discovery and Development | Best Researcher Award

Mr Victor Ajayi, University of Medical sciences Ondo Nigeria, Nigeria

Mr. Oluwadamilola Victor Ajayi is a distinguished academic and researcher in human physiology 🧬, with a B.Tech, M.Sc., and M.Phil. from reputable institutions. His groundbreaking research focuses on anti-ulcerogenic and antioxidant effects, phytochemical profiling, and bioactive compounds’ therapeutic roles 🩺. With over a decade of teaching experience at UNIMED 🎓, he excels in curriculum development and research mentorship. A member of esteemed bodies like PSN and Physoc 🏅, Mr. Ajayi actively engages in advancing physiology through publications and conferences. His dedication to science and education makes him a standout contributor in his field 🌍.

Publication Profile

orcid

Educational Backgrounds

Victor Ajayi’s academic journey spans several prestigious institutions. He is currently pursuing an M.Phil in Human Physiology at the Federal University of Technology, Akure (FUTA), starting in November 2024. He previously attended the University of Medical Sciences (UNIMED), Ondo, from August 2022 to December 2024, and earned his M.Sc. in Human Physiology from the University of Ibadan in November 2018. Victor completed his B.Tech in Human Physiology at Ladoke Akintola University of Technology (LAUTECH) in November 2011. His earlier academic milestones include WAEC (2009) and NECO (2002). 🎓📚👨‍🎓

Work Experience

Victor Ajayi has a diverse work experience spanning various roles in academia and healthcare. He started with industrial training as a Technologist at Spring Specialist Hospital in 2010, followed by NYSC at Ondo State School of Nursing, where he taught Physiology and Anatomy. Victor later worked as a teacher and guest tutor at different institutions, including Integrity Nursery, Ondo State School of Nursing, and several colleges. At the University of Medical Sciences, he serves as an Assistant Lecturer, course coordinator, and level adviser, while also supervising graduate students. His contributions to Physiology education remain invaluable. 🏥📚👨‍🏫

Membership

Mr. Victor Ajayi D. is an active member of esteemed professional bodies such as the Physiological Society of Nigeria (PSN) and The Physiological Society (Physoc). Over the years, he has attended several notable conferences and workshops, including the 28th and 29th Scientific Conferences of PSN at the University of Ilorin in 2008 and 2009, and the 31st conference at Lagos State University in 2011. He also participated in workshops on pedagogy, effective communication, animal ethics, and integrated registration. His dedication to continued learning is evident in his certified seminar attendance, such as the Bioinformatics and Genomics course in October 2024. 📚🔬🧑‍🏫

Community and Professional Engagement

Mr. Victor Ajayi has consistently showcased remarkable leadership in professional communities. As a dedicated member of esteemed organizations such as the Physiological Society of Nigeria (PSN) and The Physiological Society (Physoc), he has made significant contributions to the advancement of his field. His active participation in numerous conferences and workshops underscores his commitment to continuous learning and staying at the forefront of his profession. Through these engagements, Mr. Ajayi has demonstrated a passion for professional growth and a commitment to fostering collaboration within the scientific community. His involvement continues to inspire and influence others in the field. 💼📚

Accolades and Recognition

Mr. Victor Ajayi has made significant contributions to research, education, and professional development, positioning him as a strong contender for the Best Researcher Award. Although his CV does not highlight specific prior awards, his innovative approaches to addressing physiological challenges and his commitment to advancing scientific knowledge demonstrate his potential. Additionally, his dedication to mentoring the next generation of researchers reflects his passion for nurturing talent and fostering academic growth. Mr. Ajayi’s work continues to inspire and impact the research community, showcasing his outstanding ability to drive change and innovation in his field. 🏆📚🔬

Research Focus

Mr. Victor Ajayi’s research focuses on the anti-inflammatory and anti-oxidative effects of pasteurized yoghurt in mitigating gastric ulceration induced by indomethacin in male Wistar rats. This study delves into gastrointestinal health and the potential therapeutic benefits of food-based interventions in inflammatory conditions. His work contributes to pharmacology, nutritional science, and biomedical research with an emphasis on how diet and natural substances can influence disease progression and provide alternative treatments. This aligns with the field of Pharmacological Toxicology and Gastroenterology, exploring the intersection of nutrition and pharmacology in disease management. 🧑‍⚕️🍽️💊

Publication Top Notes

Anti-inflammatory and anti-oxidative effect of pasterurised yoghurt in indomethacin induced gastric ulceration in male Wistar rats

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Joonsik Jo | Formulation Science | Best Researcher Award

Published on by Top Pharmaceutical

Joonsik Jo | Formulation Science | Best Researcher Award

Mr Joonsik Jo, The Seoul Institute, South Korea

Mr. Joonsik Jo is a distinguished researcher in Transportation Planning & Engineering with expertise in using Explainable Artificial Intelligence (XAI) to analyze the relationship between pedestrian volume and air quality 🌍🚶. He holds a Master’s and Bachelor’s degree in Transportation Engineering from the University of Seoul 🎓. His impactful projects include public transportation feasibility studies and AI-driven vehicle management systems 🚆🤖. Mr. Jo’s publication in Clean Technologies and Environmental Policy and his Best Paper Presentation Award at the Korean Society of Transportation highlight his significant contributions to sustainable urban mobility 🌱.

Publication Profile

scopus

Educational Background

Mr. Joonsik  holds a Master’s degree in Transportation Engineering from the University of Seoul, where his research focused on the intersection of artificial intelligence and transportation systems 🤖🚗. This solid academic foundation is supported by his Bachelor’s degree in Transportation Engineering from the same institution, showcasing his long-standing commitment to the field 📚🎓. His innovative approach to research and dedication to advancing transportation technologies makes him a standout figure in his area of expertise 🌟. Mr. Jo’s work combines the principles of engineering with cutting-edge AI, contributing to the evolution of smart transportation systems and sustainable urban mobility 🚀.

Awards and Recognition

Mr. Joonsik Jo has been honored with the Best Paper Presentation Award at the 87th Conference of the Korean Society of Transportation 🚗📚. This prestigious recognition further underscores the exceptional quality and impact of his research in the field of transportation studies. By effectively communicating complex ideas, Mr. Jo has demonstrated his ability to present innovative insights that contribute significantly to the academic community. His achievement highlights both his dedication to advancing knowledge and his skill in conveying intricate concepts with clarity 🎤🏆. This award serves as a testament to his hard work and valuable contributions to the transportation sector.

Employment History

Mr. Joonsik Jo is currently pursuing his Master’s degree in Transportation Engineering at the University of Seoul 🎓🚗. As a dedicated student, he is gaining advanced knowledge and expertise in the field of transportation, focusing on developing innovative solutions to improve infrastructure and systems. His academic journey at a prestigious institution like the University of Seoul reflects his commitment to excellence in transportation engineering. By immersing himself in research and coursework, Mr. Jo is building a strong foundation to contribute to the future of sustainable and efficient transportation solutions 🌍🔧. His passion for the field drives his continuous growth and success.

Research Projects

Mr. Joonsik Jo has made significant contributions to several high-impact research projects, focusing on urban transportation systems, sustainability, and efficiency 🌍🚇. His work on the Feasibility Study and Commercialization Plan for Public Transportation in the Uiwang-Gunpo-Ansan Area, as well as the Traffic Demand & Pedestrian Flow Estimation for the GTX Uijeongbu Station Transfer Center Construction Project, showcases his dedication to improving public transportation planning and infrastructure 🏙️🚶‍♂️. Additionally, Mr. Jo’s research on detecting MERS virus spread in public transport and developing an Autonomous Shared Vehicle Management System using AI deep learning techniques highlights his innovative, multidisciplinary approach to solving real-world challenges 🤖💡.

Published Work

Mr. Joonsik Jo has made a remarkable contribution to the field through his publication in Clean Technologies and Environmental Policy (SCIE journal) 🌿📖. His research explores the relationship between air quality and walkability using cutting-edge Explainable AI (XAI) techniques 🌬️🤖. This innovative approach allows for a deeper understanding of environmental and transportation issues, which is vital for creating sustainable and livable cities 🏙️💚. By applying XAI to these complex challenges, Mr. Jo is helping to pave the way for smarter urban planning and more effective solutions to improve both air quality and pedestrian infrastructure.

Research Focus

Mr. Joonsik Jo’s research primarily focuses on urban transportation systems, environmental impact, and the use of artificial intelligence (AI) for data analysis in transportation planning. His work includes topics such as predicting passenger congestion in subways 🚇, travel demand management to mitigate climate change 🌍, and the impact of transportation on air quality 🌫️. Additionally, he explores the relationship between air quality and walkability 🏙️ using explainable AI techniques. His contributions also include environmental comparisons between different public transport systems, such as super bus rapid transit and trams 🚍🚋. His research aims to enhance sustainable urban development and improve environmental quality.

Publication Top Notes

A hybrid clustering–regression approach for predicting passenger congestion in a carriage at a subway platform

Travel demand management strategies to mitigate climate change

Revealing relationships between levels of air quality and walkability using explainable artificial intelligence techniques

Environmental benefit comparison between super bus rapid transit and tram systems

Air Quality Modeling Using Real-time Urban Big Data

Dr. ANANDARUP GOSWAMI| Drug Discovery and Developmenty|Best Researcher Award

Published on by Top Pharmaceutical

Dr. ANANDARUP GOSWAMI| Drug Discovery and Development|Best Researcher Award

Dr. ANANDARUP GOSWAMI at Vignan’s Foundation for Science, Technology and Research,India

PROFILE  

Google scholar

Early Academic Pursuits 🎓

Dr. Anandarup Goswami’s passion for chemistry was ignited during his early years of education. He completed his undergraduate studies with a B.Sc. (Hons.) in Chemistry from the prestigious Presidency University in Kolkata, one of India’s top institutions for the sciences. He further honed his expertise by pursuing an M.Sc. in Chemistry at the renowned Indian Institute of Technology (IIT) Kanpur, known for producing some of the finest scientific minds in the country. Dr. Goswami’s dedication to his academic pursuits earned him a place in Cornell University, USA, where he completed his Ph.D. His doctoral work marked the beginning of his contribution to cutting-edge research, where he specialized in advanced areas of chemistry. His journey did not stop there; he went on to complete his postdoctoral research at Rutgers University, USA, and Palacky University, Czech Republic, enhancing his research portfolio and gaining exposure to diverse scientific methodologies and innovative research techniques.

Professional Endeavors 🧪

Dr. Anandarup Goswami joined Vignan’s Foundation for Science, Technology and Research (VFSTR) as an Associate Professor in November 2026. His professional career spans a broad spectrum of roles, from teaching and mentoring students to leading groundbreaking research. He has served as a Ph.D. supervisor and has guided numerous students in drug degradation studies and nanocatalysis development for environmental applications. His work at VFSTR has helped shape the future of young scientists while driving forward critical research in sustainable chemistry.

Dr. Goswami also holds numerous editorial appointments, including being a member of the Editorial Board of Current Indian Science (Bentham) and a Review Editor for Green and Sustainable Chemistry (Frontiers). His contributions to these roles highlight his prominence in the scientific community, where he is trusted to review and oversee publications in these significant areas of research.

Contributions and Research Focus 🔬

Dr. Goswami’s research contributions are primarily centered around two critical areas: pharmaceutically relevant compounds and sustainable nanocatalysts. His extensive work in the isolation and in-depth characterization of degradation products of pharmaceutical compounds has significant implications for drug safety, efficacy, and regulatory science. In tandem, his pioneering work on the development of nanocatalysts for environmental applications addresses pressing issues related to sustainability and environmental protection.

Dr. Goswami’s work emphasizes catalysis, energy conversion, and material science, offering solutions to some of today’s most critical challenges. His contributions span more than 50 peer-reviewed publications, including in highly reputed journals such as Journal of the American Chemical Society (JACS), Angewandte Chemie, and Nature Chemistry. Moreover, his book, Solvent-Free Methods in Nanocatalysis: From Catalyst Design to Applications, co-edited with prominent scientists, reflects his authority in the field of nanocatalysis.

Accolades and Recognition 🏆

Dr. Goswami’s research accomplishments have been widely recognized in the scientific community. With an h-index of 27 on Google Scholar and 26 on Scopus, along with more than 8,800 citations, his work has made a lasting impact on his field. He has received recognition for his contributions to nanocatalysis and drug degradation, and his research has gained international acclaim.

One of his notable patents, US010722743B2, titled Multicatalyst Polyelectrolyte Membranes and Methods of Utilizing the Same, was developed during his time at Rutgers University, USA. This patent reflects his innovative approach to solving complex problems in material science and catalysis.

Dr. Goswami’s contributions have also led him to collaborate with renowned scientists globally, including Prof. Tewodros Asefa from Rutgers University, USA, and Prof. Radek Zboril from RCPTM, Czech Republic. These collaborations have expanded his research’s scope and influence, enabling him to contribute to international advancements in chemistry.

🎓Publication 

Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis

  • Authors   : Manoj B Gawande, Anandarup Goswami, François-Xavier Felpin, Tewodros Asefa, Xiaoxi Huang, Rafael Silva, Xiaoxin Zou, Radek Zboril, Rajender S Varma
  • Journal    :Chemical reviews
  • Year         :2016

obalt‐Embedded Nitrogen‐Rich Carbon Nanotubes Efficiently Catalyze Hydrogen Evolution Reaction at All pH Values

  • Authors   : Xiaoxin Zou, Xiaoxi Huang, Anandarup Goswami, Rafael Silva, Bhaskar R Sathe, Eliška Mikmeková, Tewodros Asefa
  • Journal    :Angewandte Chemie International Edition
  • Year         :2014

Core–shell nanoparticles: synthesis and applications in catalysis and electrocatalysis

  • Authors   : Manoj B Gawande, Anandarup Goswami, Tewodros Asefa, Huizhang Guo, Ankush V Biradar, Dong-Liang Peng, Radek Zboril, Rajender S Varma
  • Journal    :Chemical Society Reviews
  • Year         :2015

Covalent functionalization of monolayered transition metal dichalcogenides by phase engineering

  • Authors   : Damien Voiry, Anandarup Goswami, Rajesh Kappera, Cecilia de Carvalho Castro e Silva, Daniel Kaplan, Takeshi Fujita, Mingwei Chen, Tewodros Asefa, Manish Chhowalla
  • Journal    :Nature chemistry
  • Year         :2015

Covalent functionalization of monolayered transition metal dichalcogenides by phase engineering

  • Authors   :Damien Voiry, Anandarup Goswami, Rajesh Kappera, Cecilia de Carvalho Castro e Silva, Daniel Kaplan, Takeshi Fujita, Mingwei Chen, Tewodros Asefa, Manish Chhowalla
  • Journal    :Nature Publishing Group
  • Year         :2015